Litcius/Paper detail

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

Franck Pagès, Thierry André, Julien Taı̈eb, Déwi Vernerey, Julie Henriques, Christophe Borg, Florence Marliot, Rim Ben Jannet, C. Louvet, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, R. Faroux, Amos Kirilovsky, Alex Duval, Pierre Laurent‐Puig, M. Svrcek, Fabienne Hermitte, Aurélie Catteau, Jérôme Galon, J Emile

2020Annals of Oncology153 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineOxaliplatinHazard ratioOncologyProportional hazards modelColorectal cancerCohortStage (stratigraphy)Confidence intervalMicrosatellite instabilityAdjuvant therapyGastroenterologyCancerChemistryMicrosatelliteBiologyPaleontologyBiochemistryGeneAlleleColorectal Cancer Surgical TreatmentsCancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study | Litcius